Black Diamond Therapeutics
IPO News: Filed S-1/A: Black Diamond Therapeutics, Inc. Launches 8.9mm Share IPO with $16.00 - $18.00 Marketing Range
Black Diamond Therapeutics

Black Diamond Therapeutics, Inc.


Initial Filing Date:  01/03/20

Launch Date:  01/21/20

Price Range:  $16.00 - $18.00

Shares Offered (Pre-Shoe | mm):  8.9

Primary Shares (mm):  8.9

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $151.3

% Secondary:  0.0%

Shares Outstanding (mm):  32.6

Market Value at Midpoint (mm):  $554.8

Offering as % of Market Value:  27.3%

Bookrunners:  JPM | JEFF | COWN

Co-Managers:  CG

Major Holders:  Versant Venture Capital | New Enterprise Associates | RA Capital | Boxer Capital | Executives and Directors (CEO, David Epstein)

Description:  Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Our goal is to bring precision oncology medicine to a greater number of patients. We target undrugged mutations in patients with genetically-defined cancers.

Note:  Emerging Growth Company; This offering includes a directed share program


Reference Link:  S-1/A